Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control. GNH USA supplies Maysiglu as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used to manage type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - As monotherapy when diet and exercise alone are insufficient: provides additional glycaemic control. - In combination with metformin: enhances overall glucose‑lowering effect. - As part of fixed‑dose combinations with other oral agents: simplifies regimen while maintaining efficacy.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Nasopharyngitis: upper respiratory tract inflammation. - Upper respiratory infection: symptoms of cold or flu. - Dizziness: occasional light‑headedness. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia, sometimes chronic. - Hepatic injury: elevated liver enzymes or hepatitis. - Bullous pemphigoid: blistering skin disorder. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Before initiating sitagliptin therapy, several safety considerations should be reviewed. - Renal function: assess creatinine clearance and adjust dose if necessary. - History of pancreatitis: monitor for recurrent abdominal pain. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Elderly patients: start at lower dose and monitor for adverse events. - Hepatic impairment: evaluate liver function and consider dose modification. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas (e.g., glipizide): heightened hypoglycaemic potential. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma levels. - Strong CYP2C8 inducers (e.g., rifampin): may reduce sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for possible anticoagulant effect changes. - Digoxin: observe for altered serum concentrations. - Diuretics: watch renal function and electrolyte balance. - NSAIDs: assess renal function, especially in patients with pre‑existing kidney disease.